SSBI Stock News 11.30 05/13/2014 08:33:49 Summit State Bank

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Summit State Bank (SSBI) 11.30 $SSBI

Summit State Bank Reports 21% Increase in Profitability and Declaration of Dividend
GlobeNewswire - Tue Apr 29, 9:29AM CDT
Summit State Bank (Nasdaq:SSBI) today reported net income for the quarter ended March 31, 2014 of $1,210,000, a 21% increase over the quarter ended March 31, 2013. A quarterly dividend of $0.11 per share was declared for common shareholders.

Cost Containment Continues at Westamerica - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 4:10PM CDT
On March 25, 2014, we have issued an updated research report on Westamerica Bancorp.

SVB Financial Upped to Strong Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 31, 4:00PM CDT
SVB Financial has been witnessing rising earnings estimates on the back of strong fourth-quarter 2013 results, which included improved revenues, growth in deposits & loans and a steady capital position.

Preferred Bank Crafts 52-Week High - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 27, 9:35AM CDT
Shares of Preferred Bank hit a new 52-week high of $26.79 during the first half of the trading session on March 26.

Bank of Hawaii Hits 52-Week High - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 25, 3:45PM CDT
Shares of Bank of Hawaii Corporation crafted a new 52-week high, touching $61.36 on Mar 24.

Mixed Thoughts on Zions - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 13, 4:05PM CDT
Recently we issued an updated research report on Zions Bancorp. (ZION) based on mixed sentiments.

Peregrine Announces Ch-6 Independent Diamond Valuation Results
Marketwire - Wed Feb 26, 7:11AM CST
Peregrine Diamonds Ltd. ("Peregrine" or "the Company" (TSX: PGD) is pleased to announce the results of an independent diamond valuation for a 1,013.5 carat parcel of commercial-size diamonds recovered from the CH-6 kimberlite pipe. The average price was US$213 per carat and the entire parcel was valued at US$215,605. The modelled price ranged from a minimum of US$162 per carat to a high of US$236 per carat with a base case modelled price of US$188 per carat. The grade of the 404.2 tonne bulk sample that yielded the 1,013.5 carat parcel was 2.58 carats per tonne ("CPT" for diamonds larger than the 1.18 mm square mesh sieve size. Within the parcel, the four largest diamonds weighing 8.87, 5.83, 4.62 and 4.11 carats had per carat market values of US$4,076, US$3,455, US$2,900 and US$2,633 respectively. The CH-6 kimberlite is located on Peregrine's 100 percent-owned Chidliak diamond project ("Chidliak" or "the Project", on Baffin Island, 120 kilometers from Iqaluit, the capital of Nunavut, Canada.

Balanced Risk-Reward for PNC Financial - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 20, 4:40PM CST
On Feb 18, 2014, we issued an updated research report on The PNC Financial Services Group. Inc.

BofI Holding Touches 52-Week High - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 19, 12:20PM CST
Shares of BofI Holding achieved a new 52-week high, reaching $87.36 in the second half of the trading session on Feb 18. Notably, the stock closed the session at $86.80, which reflects a solid year-to-date return of 14.3%.

Preferred Bank Crafts New 52-Week High - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 18, 2:56PM CST
Shares of Preferred Bank hit a 52-week high, touching $23.18 in the second half of the trading session on Feb 14.

Zions Disposes Risky CDOs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 13, 8:20AM CST
In compliance with the final version of the Volcker Rule, Zions Bancorporation recently completed the divesture of certain collateralized debt obligation securities (CDOs).

Summit State Bank Reports a 25% Increase in Earnings for 2013 and Declaration of Dividend
GlobeNewswire - Mon Jan 27, 6:00PM CST
Summit State Bank (Nasdaq:SSBI) today reported net income for the year ended December 31, 2013 of $4,321,000, a 25% increase over 2012. Earnings per share increased to $0.85 in 2013 from $0.62 in 2012.

Summit State Bank Announces Election of Directors
GlobeNewswire - Tue Jul 30, 6:00PM CDT
Summit State Bank (Nasdaq:SSBI) today announced the election of directors. The following were elected directors: Jeffrey B. Allen, James E. Baxter II, James E. Brush, Josh C. Cox, Jr., John F. DeMeo, Michael J. Donovan, Richard A. Dorr, Thomas M. Duryea, Todd R. Fry, Allan J. Hemphill, Samuel G. Kapourales, Ronald A. Metcalfe, Richard E. Pope, Nicholas J. Rado, Marshall T. Reynolds, and Eugene W. Traverso. Allan Hemphill has been elected as the Chairman of the Board.

Summit State Bank Reports 64% Increase in Profitability and Dividend Increase
GlobeNewswire - Mon Apr 29, 7:14PM CDT
Summit State Bank (Nasdaq:SSBI) today reported net income for the quarter ended March 31, 2013 of $1,002,000, a 64% increase over the quarter ended March 31, 2012. A quarterly dividend of $0.11 per share was declared for common shareholders.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Dr. Boonipat Inspires Future Women Surgeons at Texas Tech

Updated Category News Views 75

Sowing Surgical Seeds in Lubbock In Lubbock, Texas, something meaningful unfolded—an event the big market players would hardly blink at, but a significant step for the future of medicine. Led by Dr. Thanapoom "Mo" Boonipat, the founder of FacePlus Plastic Surgery Institute, a unique suturing workshop provided premed students at Texas Tech University hands-on experience...

Continue Reading
Hims & Hers Faces FTC Heat: Investor Class Action Looms

Updated Category News Views 176

Trouble Is Brewing for Hims & Hers Investors This isn't your typical quiet stroll through the park when it comes to Hims & Hers Health, Inc. (NYSE: HIMS). We're talking about a full-blown legal showdown that's unfolding faster than you can say 'telehealth scandal.' October 25, 2026, saw the kind of announcement that makes seasoned investors' hearts skip a beat if they've...

Continue Reading
Kelun-Biotech's Sacituzumab Tirumotecan Shows Promise in NSCLC

Updated Category News Views 324

Kelun-Biotech's Recent Breakthrough Grab your coffee, and let's chat about something that might just change the lung cancer treatment game: Kelun-Biotech's sacituzumab tirumotecan, or sac-TMT, showing some serious promise in a Phase III trial. With numbers that could make any investor sit up a little straighter, this study has turned heads at the European Society for...

Continue Reading
Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Updated Category News Views 393

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Continue Reading
BAIC FOTON Eyes African Market with Strategic Moves

Updated Category News Views 90

Revving Up for Africa Alright, gearheads and number-crunchers, strap in. BAIC FOTON is making headlines again, and this time they’re zooming right into Africa—like they're claiming pole position on a circuit that's been ignored by many. They’re calling it a “Drive to Great!” but what does that mean for us investors who aren’t just in it for the entertainment?...

Continue Reading
Survivors Secure $800M Settlement with NY Archdiocese

Updated Category News Views 345

Massive Settlement: A Long-Awaited Justice Here's a different kind of news that's hitting like a thunderbolt. Over 1,300 survivors of abuse have finally struck a landmark deal with the Archdiocese of New York. Not only are the numbers staggering, but the relief for these individuals is palpable. We're talking about more than $800 million on the table here. That's some...

Continue Reading
Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 249

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading
Sinclair Faces Labor Lawsuit for Break-time Violations

Updated Category News Views 199

Sinclair Television Caught in Labor Law Storm When you think of flaring tempers and boardroom brawls, you typically don't think of your everyday TV station. But right now, Sinclair Television of California, LLC is in the hot seat, accused of playing fast and loose with wage packets—specifically, allegedly denying meal periods and rest breaks that California labor laws...

Continue Reading
Miranda Lambert Lights Up Red Kettle Campaign

Updated Category News Views 209

A Star-Studded Start to the Season of Giving Miranda Lambert is set to dazzle audiences yet again, and if there's one thing this country music titan knows, it's how to crank up the heartstrings while fanning the flames of generosity. She'll take to the stage at AT&T Stadium this Thanksgiving during the Dallas Cowboys game, bringing a powerful performance to light up the...

Continue Reading
Lilly's Olomorasib: New Data Sparks Hope for G12C NSCLC

Updated Category News Views 186

New Data Unveiling Potential Shifts in NSCLC Treatment Man, if there's one thing the oncology world craved, it's progress against KRAS G12C-mutant non-small cell lung cancer (NSCLC). We're talking about a challenge as tough as a two-dollar steak. But hey, Eli Lilly's (NYSE:LLY) putting some serious cards on the table with olomorasib, and folks at the ESMO 2026 Congress...

Continue Reading

Top 5 Most Recently Viewed Articles

Earnings Forecast and Expectations for Anika Therapeutics

Updated Category News Views 118

Understanding Anika Therapeutics's Upcoming Earnings Anika Therapeutics (NASDAQ: ANIK) is scheduled to unveil its quarterly earnings report soon. This anticipation is palpable amongst investors who are eager to discover the latest financial insights that the company has to offer. As the date approaches, many are analyzing the potential earnings and what they might mean...

Continue Reading
QYOU Media's Strategic Shift Towards a Creator-Focused Future

Updated Category News Views 202

QYOU Media Completes Sale of Q TV Broadcast Channel QYOU Media Inc., a leading player in the global creator economy, has successfully completed the sale of its free-to-air broadcast channel known as Q TV. This strategic move, executed through its subsidiary QYOU Media India Pvt. Ltd., marks a significant shift towards embracing new growth avenues focused on social media...

Continue Reading
Understanding Recent Disclosures from Octopus Investments

Updated Category News Views 106

Key Disclosure Information by Octopus Investments PUBLIC DISCLOSURE OF INVESTMENT INTERESTS In line with market regulations, Octopus Investments Ltd reveals crucial data regarding interests in relevant securities, particularly concerning Marlowe plc. This disclosure adheres to Rule 8.3 of the Takeover Code, aimed at maintaining transparency in the investment community....

Continue Reading
LiTime's Innovative Battery Solutions Shine in European RV Market

Updated Category News Views 297

LiTime Introduces H190 Series Batteries for RV Enthusiasts At a recent trade show, LiTime made quite the impression with its first participation in Europe’s premier RV exhibition, the Il Salone del Camper. The event, which boasts a large turnout, allowed the company to spotlight its innovative H190 series of batteries tailored for motorhomes. Targeted Designs for Unique...

Continue Reading
Oncolytics Biotech Appoints Jared Kelly as New CEO to Lead Growth

Updated Category News Views 263

Oncolytics Biotech Welcomes New Leadership for Future Growth Oncolytics Biotech Inc. (NASDAQ: ONCY), a notable player in the clinical-stage biotechnology sector focused on immunotherapy for cancer treatment, has proudly appointed Jared Kelly as its new Chief Executive Officer and as a member of its Board of Directors. This significant transition marks a pivotal moment for...

Continue Reading